Earnings setup and analyst positioning before the Sept. 1 release
Medtronic plc (NYSE:MDT) is scheduled to release its first-quarter fiscal results before the opening bell on Tuesday, Sept. 1, putting the medical-device maker at the center of this week's earnings calendar. The Benzinga consensus tracker points to quarterly earnings of $1.39 per share, up from $1.26 a year earlier, on revenue of $9.54 billion, compared with $8.54 billion in the year-ago period. Ahead of the print, TD Cowen analyst Joshua Jennings kept a Buy rating on Medtronic on Friday and lifted his price target from $100 to $110, framing the setup as constructive for income-oriented investors eyeing the dividend alongside the results.
How MDT shares typically trade after earnings
Trefis reviewed Medtronic's post-earnings trading history over the last five years and found a mixed record that has tilted more negative than positive on the day of the report. Across 19 earnings observations, shares posted a positive one-day return in eight cases and a negative one-day return in eleven, a roughly 42% hit rate that ticks up to 45% when the sample is narrowed to the last three years. Median gains on positive days reached 2.9%, while median losses on down days came in at 3.1%; the worst one-day drop was 7.3% and the best one-day pop was 5.7%. The same dataset shows that the strongest correlation between short- and medium-term post-earnings windows is between the one-day and 21-day returns, a pairing that Trefis flags as the most useful for event-driven positioning.
Scale and operating profile heading into the report
Beyond the consensus line items, Medtronic enters the print as a $117 billion market-cap healthcare equipment company with $36 billion in trailing-twelve-month revenue and $6.8 billion in operating profit. Net income over the same span was $4.8 billion, underscoring the operating base that the Sept. 1 release is expected to update. Earlier in the year, the stock posted a 5.7% gain on the day after the June 3, 2026 earnings release and an 11.2% follow-through over the next five sessions, the strongest one-day and five-day reactions in the five-year window Trefis tabulated.
What to watch when the report lands
The first flash point will be whether Medtronic's quarterly EPS and revenue clear the published consensus of $1.39 and $9.54 billion, and how the headline compares with the year-ago figures of $1.26 and $8.54 billion. Guidance commentary in the release and on the conference call will be the second test for the TD Cowen $110 price target, which was issued ahead of the print. Investors using Trefis's framework will also be tracking whether the one-day reaction tracks toward the historical 42%-45% positive-return base rate or breaks with the five-year pattern.
Share this article
